Top

Published in:

01-10-2021 | Glioma | Short Report

Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab

Authors: Yong Wang, Jun Xu, Ningning Luo, Chuang Qi, Rongjie Tao

Published in: Investigational New Drugs | Issue 5/2021

Summary

Diffuse midline gliomas (DMGs), which are malignant, fast-growing and entail a poor prognosis, are a rare subtype of glial tumor. DMGs harboring H3 K27-mutation are a novel entity with a poorer prognosis than the H3 wildtype and are categorized as a grade IV glioma. Histone-mutated DMGs characterized by a midline location occur more commonly in children and less frequently in adults. Considering the DMG treatment is limited, there is an urgent need for effective therapeutic strategies. Olaparib is a poly-adenosine diphosphate-ribose polymerase inhibitor, which has been reported to inhibit glioma in preclinical and clinical trials. Olaparib plus bevacizumab has been successfully used in ovarian cancer. However, the application of olaparib in DMGs has not been reported yet. Herein, we firstly reported that an adult DMG patient benefited from olaparib combined with bevacizumab and achieved complete remission. The duration of response and overall survival was 8 months and 16 months respectively. This report provides a promising treatment option for patients with DMG.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J, Baker SJ, St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253. https://doi.org/10.1038/ng.1102CrossRefPubMedPubMedCentral

Wang L, Li Z, Zhang M, Piao Y, Chen L, Liang H, Wei Y, Hu Z, Zhao L, Teng L, Lu D (2018) H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol 78:89–96. https://doi.org/10.1016/j.humpath.2018.04.015CrossRefPubMed

Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439–447. https://doi.org/10.1007/s00401-012-0998-0CrossRefPubMedPubMedCentral

Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C (2014) Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 128(4):573–581. https://doi.org/10.1007/s00401-014-1319-6CrossRefPubMedPubMedCentral

Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, Kühnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM (2018) Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-oncology 20(1):123–131. https://doi.org/10.1093/neuonc/nox149CrossRefPubMed

Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, Forest F, Rousselot-Denis C, Burel-Vandenbos F, Bourg V, Guyotat J, Fenouil T, Jouvet A, Honnorat J, Ducray F (2017) Characteristics of H3 K27M-mutant gliomas in adults. Neuro-oncology 19(8):1127–1134. https://doi.org/10.1093/neuonc/now274CrossRefPubMedPubMedCentral

Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 135:639–642. https://doi.org/10.1007/s00401-018-1826-yCrossRefPubMed

Schulte JD, Buerki RA, Lapointe S et al (2020) Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv 2(1):vdaa142. https://doi.org/10.1093/noajnl/vdaa142CrossRefPubMedPubMedCentral

10.

Lin GL, Wilson KM, Ceribelli M et al (2019) Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med 11(519):eaaw0064. https://doi.org/10.1126/scitranslmed.aaw0064CrossRefPubMedPubMedCentral

11.

Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung S, Rutka JT, Taylor MD, Dirks PB, Hawkins C (2015) Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic Pontine Glioma and pediatric high-grade astrocytoma. Mol Cancer Ther 14(11):2560–2568. https://doi.org/10.1158/1535-7163.MCT-15-0282CrossRefPubMed

12.

Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon SI, MacDonald J, Ewend MG, Gilbert MR, Yang C, Wu J (2017) Chemosensitivity of IDH1-mutated Gliomas due to an impairment in PARP1-mediated DNA repair. Cancer Res 77(7):1709–1718. https://doi.org/10.1158/0008-5472.CAN-16-2773CrossRefPubMedPubMedCentral

13.

Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D (2019) Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer 19(1):198. https://doi.org/10.1186/s12885-019-5413-yCrossRefPubMedPubMedCentral

14.

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P (2019) Olaparib plus Bevacizumab as first-line maintenance in ovarian Cancer. N Engl J Med 381(25):2416–2428. https://doi.org/10.1056/NEJMoa1911361CrossRefPubMed

15.

Kim DS, Camacho CV, Kraus WL (2021) Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med 53(1):42–51. https://doi.org/10.1038/s12276-021-00557-3CrossRefPubMedPubMedCentral

16.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15(8):852–861. https://doi.org/10.1016/S1470-2045(14)70228-1CrossRefPubMed

17.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian Cancer. N Engl J Med 375(22):2154–2164. https://doi.org/10.1056/NEJMoa1611310CrossRefPubMed

18.

Kim DS, Camacho CV, Nagari A, Malladi VS, Challa S, Kraus WL (2019) Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21. Mol Cell 75(6):1270–1285.e14. https://doi.org/10.1016/j.molcel.2019.06.020CrossRefPubMedPubMedCentral

19.

Keung MY, Wu Y, Badar F, Vadgama JV (2020) Response of breast Cancer cells to PARP inhibitors is independent of BRCA status. J Clin Med 9(4):940. https://doi.org/10.3390/jcm9040940CrossRefPubMedCentral

20.

Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, Hammond EM, Bristow RG (2010) Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 70(20):8045–8054. https://doi.org/10.1158/0008-5472.CAN-10-2352CrossRefPubMedPubMedCentral

21.

Gonin-Laurent N, Gibaud A, Huygue M, Lefèvre SH, Le Bras M, Chauveinc L, Sastre-Garau X, Doz F, Lumbroso L, Chevillard S, Malfoy B (2006) Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis 27(6):1266–1272. https://doi.org/10.1093/carcin/bgi356CrossRefPubMed

22.

Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H (2018) PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene 37(21):2793–2805. https://doi.org/10.1038/s41388-018-0130-6CrossRefPubMedPubMedCentral

23.

Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P (2019) Molecular pathology of tumors of the central nervous system. Ann Oncol 30(8):1265–1278. https://doi.org/10.1093/annonc/mdz164CrossRefPubMedPubMedCentral

24.

Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neuro-Oncol 143(1):87–93. https://doi.org/10.1007/s11060-019-03134-xCrossRef

25.

Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130(6):815–827. https://doi.org/10.1007/s00401-015-1478-0CrossRefPubMedPubMedCentral

Title: Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab
Authors: Yong Wang
Jun Xu
Ningning Luo
Chuang Qi
Rongjie Tao
Publication date: 01-10-2021
Publisher: Springer US
Keywords: Glioma
Glioma
Ovarian Cancer
Ovarian Cancer
Glioma
Bevacizumab
Published in: Investigational New Drugs / Issue 5/2021
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-021-01116-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2021

Author Correction to: Advances in anti-BRAF therapies for lung cancer

Effect of severe renal impairment on the pharmacokinetics of brigatinib

Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations

A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells

FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer